Head-To-Head Contrast: Demant A/S (OTCMKTS:WILYY) & Maravai LifeSciences (NASDAQ:MRVI)

Demant A/S (OTCMKTS:WILYY) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Demant A/S and Maravai LifeSciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Demant A/S	$3.48 billion	2.20	$233.91 million	N/A	N/A
Maravai LifeSciences	$185.74 million	6.12	-$130.77 million	($0.71)	-6.20

Demant A/S has higher revenue and earnings than Maravai LifeSciences.

Profitability

This table compares Demant A/S and Maravai LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Demant A/S	N/A	N/A	N/A
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Demant A/S and Maravai LifeSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Demant A/S	0	1	0	2	3.33
Maravai LifeSciences	1	0	3	0	2.50

Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 25.00%. Given Maravai LifeSciences’ higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Demant A/S.

Risk and Volatility

Demant A/S has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Insider and Institutional Ownership

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Demant A/S beats Maravai LifeSciences on 8 of the 13 factors compared between the two stocks.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.